Chordate Medical Holding AB (OSTO:CMH) EBIT: kr-25.21 Mil (TTM As of Jun. 2025)


OSTO:CMH Chordate Medical Holding AB OSTO:CMH
46 GF Score
Price kr0.16
GF Value kr26.18
! 6 Warning Signs
View Full Analysis

What is Chordate Medical Holding AB EBIT?

Chordate Medical Holding AB OSTO:CMH -60.40% 46 EBIT is kr-25.21 Mil as of Jun. 2025. GuruFocus rates OSTO:CMH with a GF Score™ of 46/100 and a GF Value™ of kr26.18. The stock has 6 warning signs investors should review.

Chordate Medical Holding AB's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2025 was kr-5.19 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was kr-25.21 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Chordate Medical Holding AB's annualized ROC % for the quarter that ended in Jun. 2025 was -156.62%. Chordate Medical Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -941.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Chordate Medical Holding AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 661.44%.


Chordate Medical Holding AB  (OSTO:CMH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Chordate Medical Holding AB's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

ROC % (Q: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Jun. 2025 ))/ count )
=-20.776 * ( 1 - 0% )/( (13.906 + 12.625)/ 2 )
=-20.776/13.2655
=-156.62 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Chordate Medical Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-20.776/( ( (1.961 + max(-4.314, 0)) + (2.453 + max(-2.195, 0)) )/ 2 )
=-20.776/( ( 1.961 + 2.453 )/ 2 )
=-20.776/2.207
=-941.37 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.377 + 1.632 + 0.0010000000000012) - (2.135 + 0 + 4.189)
=-4.314

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.155 + 1.793 + 0) - (1.4 + 0 + 2.743)
=-2.195

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Chordate Medical Holding AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2025 )
=-25.214/-3.812
=661.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chordate Medical Holding AB EBIT Related Terms


Chordate Medical Holding AB EBIT Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB EBIT Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.42 -21.74 -28.02 -29.18 -27.25

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.13 -5.68 -8.60 -5.74 -5.19

OSTO:CMH vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Chordate Medical Holding AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's EV-to-EBIT falls into.


OSTO:CMH
46GF Score
Chordate Medical Holding AB OSTO:CMH
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordate Medical Holding AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-25.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-25.21 Mil mean?
Chordate Medical Holding AB (OSTO:CMH) has a EBIT of kr-25.21 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chordate Medical Holding AB.
Is Chordate Medical Holding AB's EBIT too high?
Chordate Medical Holding AB's current EBIT is kr-25.21 Mil. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's EBIT compare to ABT and SYK?
Chordate Medical Holding AB's EBIT of kr-25.21 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chordate Medical Holding AB. Chordate Medical Holding AB's current EBIT is kr-25.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current EBIT of kr-25.21 Mil. The stock's GF Value™ is kr26.18, compared to a current price of kr0.16 — trading 99.4% below its estimated fair value. The current EBIT is kr-25.21 Mil. Chordate Medical Holding AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current EBIT is kr-25.21 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chordate Medical Holding AB (OSTO:CMH) Overvalued in 2026?

Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued. The current stock price of kr0.16 is trading 99.4% below its estimated GF Value™ of kr26.18.

Key valuation signals for OSTO:CMH:

  • EBIT: kr-25.21 Mil
  • GF Value™: kr26.18 vs. price of kr0.16 (99.4% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the OSTO:CMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for OSTO:CMH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price
kr26.18
GF Value